Working… Menu

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00591682
Recruitment Status : Suspended
First Posted : January 11, 2008
Last Update Posted : March 26, 2008
Information provided by:
Metastatix, Inc.

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : December 2008
Estimated Study Completion Date : March 2009